Mechanism and Therapeutic Strategy of Secondary Failure to Anti-Tumor Necrosis Factor-α Monoclonal Antibody Treatment for Crohn's Disease

Publisher： Karger

E-ISSN： 1421-9867|88|1|17-19

ISSN： 0012-2823

Source： Digestion, Vol.88, Iss.1, 2013-06, pp. : 17-19

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Anti-Tumor Necrosis Factor Nonresponders in Crohn’s Disease: Therapeutic Strategies

By  

Digestive Diseases, Vol. 27, Iss. 3, 2009-09 ,pp. : 351-357

Karger

Access to resources Recommend Favorite

Suspected de novo Hepatitis B in a Patient Receiving Anti-Tumor Necrosis Factor Alpha Therapy for the Treatment of Crohn's Disease

By  

Case Reports in Gastroenterology, Vol. 8, Iss. 1, 2014-01 ,pp. : 44-50

Karger

Access to resources Recommend Favorite

Treatment of Dermatomyositis and Polymyositis with Anti-Tumor Necrosis Factor-α: Long-Term Follow-Up

By  

European Neurology, Vol. 52, Iss. 1, 2004-07 ,pp. : 61-63

Karger

Access to resources Recommend Favorite

Decrease in the levels of anti-cyclic citrullinated peptide antibody in Japanese patients with rheumatoid arthritis who responded to anti-tumor necrosis factor-α

By Onishi Sachiko   Yoshio Taku   Nagashima Takao   Minota Seiji  

Modern Rheumatology, Vol. 20, Iss. 5, 2010-10 ,pp. : 528-530

Springer Publishing Company

Access to resources Recommend Favorite

The long-term outcome of anti-tumor necrosis factor-α therapy related to fecal calprotectin values during induction therapy in pediatric inflammatory bowel disease

By Kolho Kaija-Leena   Sipponen Taina  

Scandinavian Journal of Gastroenterology, Vol. 49, Iss. 4, 2014-04 ,pp. : 434-441

Informa Healthcare

Access to resources Recommend Favorite